Fungal Species: Panaeolus

Drug–drug interactions involving classic psychedelics: A systematic review

mycolabadmin

This review examined how psychedelic drugs like LSD and psilocybin interact with other medications people might be taking. Researchers found that certain psychiatric medications like antipsychotics can block the effects of psychedelics, while other drugs may enhance them. The study highlights the importance of understanding these interactions for safe therapeutic use of psychedelics in clinical settings.

Read More »

Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US

mycolabadmin

Researchers are studying psilocybin, a compound from certain mushrooms, as a potential treatment for depression, anxiety, and addiction. The United States has significantly more clinical trials underway than the European Union, reflecting different regulatory approaches and funding levels. While US trials progress faster, EU trials emphasize safety and careful evaluation. Both regions show promising results when psilocybin is combined with professional psychological support in controlled settings.

Read More »

Acute Kidney Failure and Myocarditis Triggered by Magic Mushroom Toxicity in a Patient With Prior Cocaine Exposure

mycolabadmin

A middle-aged man who used magic mushrooms along with alcohol and LSD developed severe kidney failure and heart inflammation. He had previously used cocaine, which made his condition worse by promoting blood clots throughout his body. Despite dialysis treatment, his kidneys stopped working, he developed heart problems and blood clots in major blood vessels, and he unfortunately passed away. This case highlights how dangerous it can be to mix magic mushrooms with other drugs, especially for people with a history of cocaine use.

Read More »

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds

mycolabadmin

This study compared the chemical makeup of psilocybin mushroom mycelium (the root-like growth) versus fruiting bodies (the mushrooms themselves) to understand their different therapeutic potential. While fruiting bodies contain much higher levels of psilocybin, the psychoactive compound, mycelium accumulates other beneficial compounds like α-GPC that may enhance cognition and motor function without strong psychedelic effects. This research suggests that mushroom mycelium could be developed as a non-intoxicating therapeutic alternative with its own unique health benefits.

Read More »

Dissimilar Reactions and Enzymes for Psilocybin Biosynthesis in Inocybe and Psilocybe Mushrooms

mycolabadmin

This study reveals that two different types of magic mushrooms—Psilocybe and Inocybe—make psilocybin (the active compound in magic mushrooms) using completely different enzymes and chemical pathways. Despite both mushroom types producing the same final product, they evolved their recipes independently, like two chefs arriving at the same dish through entirely different cooking methods. The research shows how evolution can solve the same problem in multiple ways and provides new enzymes that could be useful for producing psilocybin as a potential depression treatment.

Read More »
Scroll to Top